201 related articles for article (PubMed ID: 25750072)
41. HIV-1 infection and cognitive impairment in the cART era: a review.
Schouten J; Cinque P; Gisslen M; Reiss P; Portegies P
AIDS; 2011 Mar; 25(5):561-75. PubMed ID: 21160410
[TBL] [Abstract][Full Text] [Related]
42. Virologically suppressed patients with asymptomatic and symptomatic HIV-associated neurocognitive disorders do not display the same pattern of immune activation.
Vassallo M; Durant J; Lebrun-Frenay C; Fabre R; Ticchioni M; Andersen S; DeSalvador F; Harvey-Langton A; Dunais B; Cohen-Codar I; Montagne N; Cua E; Fredouille-Heripret L; Laffon M; Cottalorda J; Dellamonica P; Pradier C
HIV Med; 2015 Aug; 16(7):431-40. PubMed ID: 25981452
[TBL] [Abstract][Full Text] [Related]
43. Determinants of CD4+ T cell recovery during suppressive antiretroviral therapy: association of immune activation, T cell maturation markers, and cellular HIV-1 DNA.
Goicoechea M; Smith DM; Liu L; May S; Tenorio AR; Ignacio CC; Landay A; Haubrich R
J Infect Dis; 2006 Jul; 194(1):29-37. PubMed ID: 16741879
[TBL] [Abstract][Full Text] [Related]
44. HIV-associated anaemia before and after initiation of antiretroviral therapy at Art Centre of Minilik II Hospital, Addis Ababa, Ethiopia.
Adane A; Desta K; Bezabih A; Gashaye A; Kassa D
Ethiop Med J; 2012 Jan; 50(1):13-21. PubMed ID: 22519158
[TBL] [Abstract][Full Text] [Related]
45. Predictors of symptomatic HIV-associated neurocognitive disorders in universal health care.
McCombe JA; Vivithanaporn P; Gill MJ; Power C
HIV Med; 2013 Feb; 14(2):99-107. PubMed ID: 22994556
[TBL] [Abstract][Full Text] [Related]
46. The effects of highly active antiretroviral therapy (HAART) of stavudine, lamivudine and nevirapine on the CD4 lymphocyte count of HIV-infected Africans: the Nigerian experience.
Erhabor O; Ejele OA; Nwauche CA
Niger J Clin Pract; 2006 Dec; 9(2):128-33. PubMed ID: 17319344
[TBL] [Abstract][Full Text] [Related]
47. PET brain imaging in HIV-associated neurocognitive disorders (HAND) in the era of combination antiretroviral therapy.
Vera JH; Ridha B; Gilleece Y; Amlani A; Thorburn P; Dizdarevic S
Eur J Nucl Med Mol Imaging; 2017 May; 44(5):895-902. PubMed ID: 28058461
[TBL] [Abstract][Full Text] [Related]
48. CD4 deficit and tuberculosis risk persist with delayed antiretroviral therapy: 5-year data from CIPRA HT-001.
Collins SE; Jean Juste MA; Koenig SP; Secours R; Ocheretina O; Bernard D; Riviere C; Calnan M; Dunning A; Hurtado Rúa SM; Johnson WD; Pape JW; Fitzgerald DW; Severe P
Int J Tuberc Lung Dis; 2015 Jan; 19(1):50-7. PubMed ID: 25519790
[TBL] [Abstract][Full Text] [Related]
49. Depression and neurocognitive performance in individuals with HIV/AIDS: 2-year follow-up.
Gibbie T; Mijch A; Ellen S; Hoy J; Hutchison C; Wright E; Chua P; Judd F
HIV Med; 2006 Mar; 7(2):112-21. PubMed ID: 16420256
[TBL] [Abstract][Full Text] [Related]
50. Can high central nervous system penetrating antiretroviral regimens protect against the onset of HIV-associated neurocognitive disorders?
Vassallo M; Durant J; Biscay V; Lebrun-Frenay C; Dunais B; Laffon M; Harvey-Langton A; Cottalorda J; Ticchioni M; Carsenti H; Pradier C; Dellamonica P
AIDS; 2014 Feb; 28(4):493-501. PubMed ID: 24472743
[TBL] [Abstract][Full Text] [Related]
51. Does antiretroviral therapy improve HIV-associated cognitive impairment? A quantitative review of the literature.
Al-Khindi T; Zakzanis KK; van Gorp WG
J Int Neuropsychol Soc; 2011 Nov; 17(6):956-69. PubMed ID: 21813033
[TBL] [Abstract][Full Text] [Related]
52. Factors Associated with Immunological Discordance in HIV-Infected Patients Receiving Antiretroviral Therapy with Complete Viral Suppression in a Resource-Limited Setting.
Mingbunjerdsuk P; Asdamongkol N; Sungkanuparph S
Jpn J Infect Dis; 2015; 68(4):301-4. PubMed ID: 25720640
[TBL] [Abstract][Full Text] [Related]
53. Reversible dementia in a patient with central nervous system escape of human immunodeficiency virus.
Bogoch II; Davis BT; Venna N
J Infect; 2011 Sep; 63(3):236-9. PubMed ID: 21658774
[TBL] [Abstract][Full Text] [Related]
54. Short-term antiretroviral therapy to prevent mother-to-child transmission is safe and results in a sustained increase in CD4 T-cell counts in HIV-1-infected mothers.
Palacios R; Senise J; Vaz M; Diaz R; Castelo A
HIV Med; 2009 Mar; 10(3):157-62. PubMed ID: 19245537
[TBL] [Abstract][Full Text] [Related]
55. Neurocognitive consequences of HIV in southern India: a preliminary study of clade C virus.
Yepthomi T; Paul R; Vallabhaneni S; Kumarasamy N; Tate DF; Solomon S; Flanigan T
J Int Neuropsychol Soc; 2006 May; 12(3):424-30. PubMed ID: 16903135
[TBL] [Abstract][Full Text] [Related]
56. Plasma Cystatin C Associates With HIV-Associated Neurocognitive Disorder but Is a Poor Diagnostic Marker in Antiretroviral Therapy-Treated Individuals.
Kalayjian RC; Robertson KR; Albert JM; Fichtenbaum CJ; Brown TT; Taiwo BO;
J Acquir Immune Defic Syndr; 2019 Jun; 81(2):e49-e54. PubMed ID: 30939531
[TBL] [Abstract][Full Text] [Related]
57. Increased Intrathecal Immune Activation in Virally Suppressed HIV-1 Infected Patients with Neurocognitive Impairment.
Edén A; Marcotte TD; Heaton RK; Nilsson S; Zetterberg H; Fuchs D; Franklin D; Price RW; Grant I; Letendre SL; Gisslén M
PLoS One; 2016; 11(6):e0157160. PubMed ID: 27295036
[TBL] [Abstract][Full Text] [Related]
58. Utility of the International HIV Dementia Scale for HIV-Associated Neurocognitive Disorder.
Molinaro M; Sacktor N; Nakigozi G; Anok A; Batte J; Kisakye A; Myanja R; Nakasujja N; Robertson KR; Gray RH; Wawer MJ; Saylor D
J Acquir Immune Defic Syndr; 2020 Mar; 83(3):278-283. PubMed ID: 32032278
[TBL] [Abstract][Full Text] [Related]
59. Human immunodeficiency virus (HIV) modulates the associations between insulin resistance and cognition in the current combination antiretroviral therapy (cART) era: a study of the Women's Interagency HIV Study (WIHS).
Valcour V; Rubin LH; Tien P; Anastos K; Young M; Mack W; Cohen M; Golub ET; Crystal H; Maki PM
J Neurovirol; 2015 Aug; 21(4):415-21. PubMed ID: 25740539
[TBL] [Abstract][Full Text] [Related]
60. Neurologic complications of HIV infection.
Spudich SS; Ances BM
Top Antivir Med; 2012; 20(2):41-7. PubMed ID: 22710906
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
